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Background: Laparoscopic surgery has become the preferred approach for many procedures because of reduced
post-operative pain, better recovery, shorter hospital stay and improved cosmesis. Single incision laparoscopic
surgery is one of the many recent variants where either standard ports or a specially designed single multi-channel
port is introduced through a single skin incision. While the cosmetic advantage of this is obvious, the evidence
base for claims of reduced morbidity and better post-operative recovery is weak. This study aims to compare the
effectiveness of single port/incision laparoscopic appendicectomy with standard three-port laparoscopic
appendicectomy in adult patients at six weeks post-surgery. We also wish to assess the feasibility of a multicentre
randomised controlled trial comparing single port/incision laparoscopic surgery with standard three-port
laparoscopic surgery for other surgical techniques.
Methods and design: Patients diagnosed with suspected appendicitis and requiring surgical treatment will be
randomised to receive either standard three-port or single incision laparoscopic surgery. Data will be collected from
clinical notes, operation notes and patient reported questionnaires. The following outcomes will be considered:
1. Effectiveness of the surgical procedure in terms of:
• patient reported outcomes
• clinical outcomes
• resource use
2. Feasibility of conducting a randomised controlled trial (RCT) in the emergency surgical setting by quantifying:
• patient eligibility
• randomisation acceptability
• feasibility of blinding participants to the intervention received
• completion rates of case report forms and patient reported questionnaires
Trial registration: ISRCTN66443895 (assigned 10 March 2011, first patient randomised 09 January 2011)
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Appendicectomy is one of the most commonly per-
formed surgical procedures in general surgery. In
England (2010 to 2011), appendicectomy resulted in
47,145 operations; 41,458 of which were for an emer-
gency admission [1]. Laparoscopic surgery is the pre-
ferred approach for many abdominal procedures because
of reduced postoperative pain, more rapid recovery and
improved cosmesis, which follow a successful operation
compared with a conventional single large incision.
Whilst the long term clinical result may be similar [2],
the perception amongst many patients and surgeons of
advantage in terms of these short-term outcomes is a
powerful influence on practice. There are continuing
developments to laparoscopic surgery to reduce the size,
number and placement of incisions to both improve the
cosmetic appearance and reduce abdominal wall trauma.
One of the recent innovations is Single Incision Lap-
aroscopic Surgery. This can be either insertion of mul-
tiple ports through a small incision or through a
proprietary device with multiple channels. The funda-
mental difference to conventional multi-port laparo-
scopic surgery is to place all the ports through a single
incision which, when sited in the umbilicus, can result
in no visible scar in the abdominal wall.
The current literature largely comprises case reports
and small series detailing single port methods [3-9].
The technique has been used to perform a large variety
of procedures including appendicectomy, cholecystec-
tomy, nephrectomy, hysterectomy, oophorectomy, adre-
nalectomy, gastric bypass, Nissen fundoplication, hernia
repair, splenectomy, colon resection and liver resection.
Apart from a handful of reported randomised controlled
trials (RCTs) [3-9] the evidence base is weak and insuf-
ficient to inform practice and robustly assess claims of
reduced pain and morbidity with improved cosmesis
and faster recovery are unsubstantiated [10-15]. In
general, it is perceived that the single port/incision
technique takes longer initially than conventional lap-
aroscopic surgery and the differences in costs and safety
are unknown.
Nevertheless, there is considerable interest in introdu-
cing single port/incision surgery and there are a large
number of training courses. The public perception is
that it might become the procedure of choice if it
becomes available [16]. It is crucial that the technique be
critically evaluated during the introductory phase of im-
plementation to provide objective data to inform further
adoption and evaluation. However, the difficulty of
undertaking such an evaluation has been succinctly sta-
ted in Buxton’s law: “It is always too early [for rigorous
evaluation] until, unfortunately, it’s suddenly too late”
[17]. The introduction of laparoscopic surgery for Cho-
lystectomy is a vivid example of the ad hoc nature inwhich a new surgical intervention can be introduced
into practice and the difficulties of conducting rigorous
evaluations of its value [18]. Ideally, a definitive evalu-
ation requires a large, multicentre RCT of single port
versus three-port surgery. Currently, there is a paucity of
data to help plan and design such a large RCT. Add-
itionally, further refinement of the single port/incision
methodology is needed. There is, therefore, an urgent
need for a well conducted feasibility study to provide
preliminary results and inform the planning of such a
large RCT (for example, how to define the intervention,
which outcomes to use and when; likely throughput
rates; estimates of conversion rates). It is hoped that the
results of this study will lead to a large multicentre RCT
of single versus standard three-port laparoscopic
surgery.
This study will compare the effectiveness of single
port/incision laparoscopic appendicectomy with stand-
ard three-port laparoscopic appendicectomy in adult
patients at six weeks post-surgery. Additionally, it will
inform the feasibility of more complex single port
techniques, such as cholecystectomy. Appendicectomy is
the focus of this study because it is a common and rela-
tively simple procedure to undertake. Currently, no
RCTs of single port versus three-port surgery have been
published [8].
The specific objectives are:
 To compare the interventions in terms of patient
reported outcomes, clinical measures and resource
use.
 To assess the feasibility of a randomised controlled
trial evaluating another single port/incision
operation by quantifying patient eligibility and
acceptability, feasibility of blinding participants to
the intervention received and surgeon perception of
interventions.
Methods and design
Figure 1 provides an overview of the trial’s methodology.
Inclusion and exclusion criteria
Inclusion criteria
Patients aged 16 years and over presenting with sus-
pected appendicitis for whom laparoscopic surgical man-
agement is judged appropriate are eligible for inclusion.
Exclusion criteria
1. Patients who have had previous open abdominal
surgery through midline incision.
2. Patients who have had previous umbilical hernia
repair with mesh.
3. Patients unable to consent.
Patients aged 16 years presenting 
with suspected acute appendicitis 
Single port laparoscopic surgery 
24 hour assessment 
Feasibility:  proportion who are unaware 
of their received intervention. 
Exclusion criteria 
Previous open 
abdominal surgery 
through midline 
incision. 
Previous umbilical 
hernia repair with 
mesh. 
Patient unable to 
consent. 
Standard three port laparoscopic 
surgery 
Informed consent 
Baseline assessment 
Days 1 to 7 
Patient-reported:  Pain NRS and use of 
analgesics.
6 week assessment 
Feasibility:  proportion of those recruited with complete 
dataset at six weeks.
Patient-reported:  Body Image Questionnaire, Hospital 
Experience Questionnaire, pain numerical rating scale, 
use of analgesics, time to return to usual activities, 
hospital re-admissions, complications. 
Resource use: Resource use (using routine data)
RANDOMISATION
Peri-operative assessment 
Clinical:  Duration of operation, 
conversion and complications.
Feasibility:  surgeon’s perception of 
single port approach.  
Feasibility  
Proportion randomised (and 
reasons why not). 
Feasibility  
Potentially eligible patients 
per month and proportion 
formally considered for trial 
entry.
Assessed for eligibility 
Figure 1 Trial flow diagram.
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Participants will receive the allocated intervention, either
single port/incision laparoscopic surgery (SPILS) or
standard three-port laparoscopic appendicectomy sur-
gery. The surgical interventions will be delivered or
supervised by a surgeon who has expertise in the specific
intervention. All participating surgeons will have com-
pleted appropriate surgical training. Further details of
the interventions are given below:SPILS
A single intra-umbilical incision will be made and a
multi-channel port will be inserted. A 5 mm, 30 degree
telescope will be used to visualise the operative field.
Conventional laparoscopic instruments will be used for
the procedure. Roticulating/curved instruments will beavailable and used if required. Use of any additional
instruments or ports will be recorded. The musculo-
aponeurotic layers of the port site will be closed with ab-
sorbable sutures before closing the skin incision.Standard three-port laparoscopic surgery
Pneumoperitoneum will be established by an open tech-
nique through an intra/supraumbilical incision with a 10
to 12 mm port for initial pneumoperitoneum and inspec-
tion. A further 5 or 10 mm port will be used in the left
iliac fossa (depending on the availability of 5 mm laparo-
scopes) and a 5 mm port will be used in the hypogastrium.
Standard laparoscopic instruments will be used for the
procedure as per existing hospital protocol. The musculo-
aponeurotic layers of port sites of 10 mm and over will be
closed with absorbable sutures before closing the skin.
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the mesoappendix from the appendix with diathermy
and division of the appendix base between two endo-
loops. In more complicated cases, alternative techniques
may be used. Any variations to the regimen with justifi-
cation will be recorded.
A standard pain relief policy will be followed, where
possible. This will include one or more of the following
postoperative analgesics: paracetamol (1g QID); dihydro-
codeine, diclofenac and morphine (doses will be titrated
and recorded).Identification and enrolment of potential participants
Patients likely to require surgery for acute appendicitis
and who meet the eligibility criteria will be identified in
the general surgery units by the consultant or designated
team member. The consultant or team member will
introduce the study to the patients and provide further
details of the study by means of the Patient Information
Sheet.
The participants will keep a copy of the Patient Infor-
mation Sheet and the consent form (one copy will be
filed in the hospital notes, one given to the participants
and the top copy returned to the SCARLESS co-
ordinating office in Aberdeen). A letter and General
Practitioner (GP) Information Sheet will be sent to the
participant’s GP. Participants who initially agree to enter
the study but later decide to withdraw or become unable
to continue will be asked for consent to enable us to ac-
cess relevant NHS data in the future.
Patients who are ineligible or who do not agree to par-
ticipate in the study will be logged anonymously along
with a minimum dataset including gender, year of birth
and reason(s) for declining (if offered).Randomisation and allocation
Participants will be recruited from a single centre, Aber-
deen Royal Infirmary (UK). Following consent and col-
lection of baseline data, the local consultant/designated
team member will randomise the patient.
Participants will be randomised to one of the two
study groups in equal proportion using the randomisa-
tion application at the trial office at the Centre for
Healthcare and Randomised Trials (CHaRT), Aberdeen.
Randomisation will be stratified by gender and computer
generated permuted blocks of varying size used within
each stratum. This randomisation application will be
available 24 hours a day, seven days a week as an Inter-
active Voice Response (IVR) telephone system. Due to
the acute nature of the admission to surgery and poten-
tial difficulty in tracking patients, date of birth will also
be recorded in the randomisation process and available,
if necessary, for use in addition to the study number toidentify patients. The date of birth will not be openly
available.
Concealment of group allocation to participants
The feasibility of concealing group allocation from the
participants and the ward staff will be investigated. Al-
though blinding in the theatre is not possible given this
is a surgical trial, participants will not be informed after
their surgery of the procedure actually carried out.
Blinding of participants will be attempted by using three
hypoallergenic dressings applied at the umbilicus, in the
left lower quadrant and hypogastrium unless conversion
to open abdomen is required.
Sample size
As there were no published RCTs comparing single port
laparoscopic appendicectomy with standard three-port
laparoscopic appendicectomy when the study was
designed [8], a formal sample size calculation based
upon previous data was not possible. A sample of 80
participants recruited is anticipated over the seven-
month recruitment phase. Adopting a 5% two-sided sig-
nificance level, this would allow an effect size (Cohen’s
d) of 0.65 to be detected with 80% power for patient
reported measures, such as the Body Image Question-
naire [19]. Binary feasibility measures are likely to be
estimated with a (one-group) confidence interval of be-
tween 10 and 20% depending upon the corresponding
event rate [19].
Subsequent tasks
Following formal trial entry -
The Study Office will:
i. Inform the participant’s GP (by letter enclosing
information about SCARLESS and Study Office
contact details).
ii. Process the pain Numerical Rating Scale (NRS)
seven-day diary and the six-week participant
questionnaire.
iii. Collect the feasibility measures.
The consultant or team member will:
i. Provide the original signed consent form to the
Study Office and file the Hospital Copy of the form
in the hospital notes along with information about
SCARLESS.
ii. Inform the ward and theatre staff as appropriate of
the participant’s study participation and intervention
allocation.
iii. Complete case report forms (CRFs) as appropriate
and either enter the data directly onto the
SCARLESS website or forward the hard copies of
Malik et al. Trials 2012, 13:201 Page 5 of 8
http://www.trialsjournal.com/content/13/1/201the CRFs to the co-ordinating office at CHaRT for
electronic data entry. The data to be collected
include data required to complete randomisation;
intra- and postoperative.
iv. Return all study documentation to the Study Office
(CHaRT, Aberdeen) for archive.
Monitoring the participants
Participants will be contacted by post and phone as ap-
propriate. In case of non-return of questionnaires, the
participant will be sent a postal reminder or receive a
telephone call.
Data collection and processing
Follow-up will continue for six weeks from the date of
operation. Clinical data will be collected on participants
who will need to be followed-up in clinic, as part of their
treatment plan.
Participants will be assessed pre-operatively to confirm
eligibility and peri-operative data collected. Patient
reported outcomes (PROs) will be collected by diary
completed on days one to seven following surgery and
by postal questionnaires at six weeks post-surgery. The
components of participant follow-up are shown in the
Table 1.
Outcome measures
Primary effectiveness outcomes
The patient reported outcome measure is the patient
reported cosmesis and body image using the Body Image
Questionnaire (BIQ) [20] at six weeks; participants will
be asked five questions about their body image using the
scale on a 4-point Likert scale of:’no, not at all’; ‘a little
bit’; ‘quite a bit’; ‘yes, extremely’, two questions about
their incisional scar to be rated on a scale of 1 (veryTable 1 Source and timing of measures
Outcome measures Sou
BMI, ASA grade Case
(CRF
Duration of operation, intra-operative complication rates, conversion
rates, surgeon’s perception of single port approach
CRF
Intervention received CRF
Body Image Questionnaire (BIQ) [20] Part
(PQ)
Hospital Experience Questionnaire (HEQ) [20] PQ
Pain Numerical Rating Scale (NRS) PQ
Use of analgesics CRF
Time to return to usual activities PQ
Hospital re-admissions CRF
Complications (for example, infection, port-site hernia) CRFunsatisfied/revolting) to 7 (very satisfied/beautiful), one
further question regarding the scar using a 10-point Nu-
merical Rating Scale (NRS), and a question regarding
confidence on a 10-point numerical scale from 1 (not
very confident) to 10 (very confident). The clinical out-
come of severity of pain (Pain NRS) will be measured
using a pain scale (scale from 0 (no pain) to 10 (worst
imaginable pain)) at one to seven days.
Other patient-reported outcomes
Patient reported measures are the Hospital Experience
Questionnaire (HEQ) [20] at six weeks where partici-
pants will be asked four questions about their experience
in hospital (prior to the operation, treatment received,
pain after operation and time to normal eating) to be
rated subjectively using either a 4- or 5-level Likert scale
(‘much too long’ to ‘much too short’; ‘very bad’ to ‘very
good’; ‘no pain at all’ to ‘a lot of pain’; ‘no, not at all’ to ‘I
cannot remember’) and one rating question on their
view of the importance of different items (hospital stay,
size of scar, no complications, pain after surgery, and re-
suming normal activities and diet). Additionally, any an-
algesic usage and time to return to normal activities will
be collected.
Clinical outcomes
Analgesic use; duration of operation (minutes) and com-
plication rates; conversion rates; infection rates (intra-
abdominal and wound); related hospital re-admission
rates up to six weeks; reoperation rates and port-site
hernia up to six weeks.
Feasibility measures
Feasibility measures include eligible patients per month;
proportion formally considered for trial entry; proportionrce Timing
Peri- operative Days one to
seven diary
Six weeks
Report Form
)
▲
▲
▲
icipant Questionnaire ▲
▲
▲ ▲
and PQ ▲ ▲ ▲
▲
and PQ ▲
and PQ ▲ ▲
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unaware of their received intervention at 24 hours; pro-
portion of those recruited with complete data set at six
weeks; surgeon’s perception of SPILS approach and the
suitability of available equipment.
Resource use
Resource use will be limited to duration of operative pro-
cedure, theatre time and use of disposable instruments.
Statistical analyses
For feasibility measures, such as the proportion of eli-
gible patients who consent to randomisation, the fre-
quency and corresponding 95% confidence interval will
be calculated. Patient-reported and clinical measures will
be summarised using appropriate summary measures
(for example, frequency or mean and standard deviation)
for each treatment group. The treatment groups will be
compared at the two-sided 5% significance level. BIQ
and pain NRS (area under the curve over a seven-day
period) will be analysed using an independent t-test.
Other outcomes will be assessed using standard statis-
tical methods as appropriate, for example, comparison
of proportions Newcombe’s CI method [21] or chi-
squared test for trend [22], and independent t-test for
binary and continuous outcomes respectively. Corre-
sponding 95% confidence intervals will also be calcu-
lated. A single principal analysis is anticipated at the end
of the study following intention to treat principle
(grouped according to allocation). No imputation for
missing data will be carried out. All analyses will be con-
ducted using Stata 12 [23].
Timetable of work
The planned study duration is 12 months. The main
milestones are: months 1 to 2 NHS approvals; months 3
to 9 patient recruitment; months 10 to 11 completeB- Beginning; M – Middle; E – End (of month); (dd/mm); pro
Figure 2 SCARLESS Gannt Chart.participant follow up at 6 weeks; months 11 to 12 ana-
lysis of data, interpretation of results and report writing.
The timetable is described in the Gantt chart in
Figure 2.Endnotes
Data protection
The trial will comply with the Data Protection Act 1998
[24] and regular checks and monitoring will be in place
to ensure compliance. Data will be stored securely in ac-
cordance with the Act and archived to a secure data
storage facility. The consent form will state that other
researchers may wish to access (anonymised) data in the
future. CHaRT’s senior IT Manager (in collaboration
with the Chief Investigator) will manage access rights to
the data set.Sponsorship
The study is co-sponsored by the University of Aberdeen
and NHS Grampian.Retention of data
It is intended that data will be retained for at least five
years following the end of the study.Safety concerns
The SCARLESS trial involves laparoscopic surgical
operations for appendicectomy. Possible complications
and consequences are:Anaesthesia
All operations carried out under general anaesthesia
carry a risk of death, muscle paralysis, technical pro-
blems, adverse drug reactions and allergic responses.duced on MS Project software (Microsoft®Project 2010)
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All abdominal operations carry a risk of death, morbid-
ity, including wound infection, wound hernias, damage
to abdominal viscera, bleeding intra and post-opera-
tively, bowel obstruction, respiratory infections, lung col-
lapse, thrombo-embolic complications, complications
secondary to existing co-morbidity, for example, ischae-
mic heart disease and diabetes.
Laparoscopic abdominal surgery
Specific complications related to the laparoscopic ap-
proach include inadvertent injury to abdominal viscera
due to the restricted view associated with laparoscopy,
failure to appreciate the extent of pathology, possible
sub-optimal repair of intra-operative injuries, inadequate
closure of port sites with resulting early and late hernia-
tion, which may result in bowel obstruction. With the
single port/incision laparoscopic surgery (SPILS) the loss
of triangulation of instrumentation, generally considered
necessary in laparoscopic surgery, limits surgeon’s access
and manoeuvrability.
Procedure for reporting untoward and related serious
adverse events (SAEs)
The UK NHS National Research Ethics Service guide-
lines for reporting serious adverse events will be fol-
lowed [25]. For the purpose of SCARLESS, all SAEs,
defined as an event resulting from a participant’s appen-
dicectomy treatment that is life threatening, requires
prolongation of an existing hospital admission or re-
admission, results in significant incapacity/disability or is
considered to be an important medical event by the clin-
ical team, will be recorded on the Serious Adverse Event
Report form. In addition, SAE forms will record all
deaths for any cause during the course of the study.
A SAE that is both:
 related (resulted from administration of any of the
research procedures) and
 unexpected (that is, the type of event that is not
listed as a possible expected complication)
will be notified to the appropriate authorities (Research
Ethics Committee (REC) and co-sponsors) within the
timelines outlined in the guidelines, as detailed below.
Reporting responsibilities of the CI
The Chief Investigator (CI) or deputy will be automatic-
ally notified of all SAEs. If, in the opinion of the local
surgeon and the CI, the event is confirmed as being
related and unexpected, the CI will submit a report to
the main REC and the study sponsors within 15 days of
the CI becoming aware of it.As the trial arm to which participants are allocated
cannot be blind to the operating surgeons or theatre
staff after randomisation has occurred, unblinding is not
an issue in this trial. A record of the operative proce-
dures actually carried out will be available in the medical
notes if required clinically.
Ethical issues and arrangements
The North of Scotland Ethics Committee (NOSRES)
reviewed and approved this study on 08 December 2010
(REC reference number: 10/S0802/77).
Risks and benefits
The benefit to the participants participating in the trial
is the chance of receiving a less invasive treatment for
their appendicectomy. We believe this study does not
pose any specific risks to individual participants beyond
those of any laparoscopic surgery, provided sound clin-
ical judgement is exercised to convert to multi-port or
conventional surgery when necessary.
Information about risks and benefits and informed
consent
Participants are informed of known risks by means of
the Patient Information Sheet. Patients will have surgery
whether they are in the study or not and we anticipate
no additional risk to those who are randomised. Patients
who are ineligible or decline participation in the study
will have standard open or three-port laparoscopic sur-
gery as these are the standard types of surgeries under-
taken at Aberdeen Royal Infirmary. SPILS will only be
available to patients randomised within the trial.
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